NOVA EYE MEDICAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.26 AUD | -3.70% |
|
-5.45% | +8.33% |
| Mar. 15 | Nova Eye Medical Completes Retail Entitlement Offer | MT |
| Feb. 22 | Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +8.33% | 40.85M | - | ||
| +8.06% | 218B | B | ||
| +6.94% | 184B | B- | ||
| +13.54% | 135B | B- | ||
| -0.27% | 62.38B | A- | ||
| +11.59% | 51.37B | B+ | ||
| +7.76% | 50.9B | B+ | ||
| +1.14% | 40.87B | A | ||
| +3.21% | 36.28B | - | ||
| +26.11% | 31.88B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EYE Stock
- Ratings Nova Eye Medical Limited